Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial

O'Donoghue M. L. , Fazio S., Giugliano R. P. , Stroes E. S. G. , Kanevsky E., Gouni-Berthold I., ...More

CIRCULATION, vol.139, no.12, pp.1483-1492, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 139 Issue: 12
  • Publication Date: 2019
  • Doi Number: 10.1161/circulationaha.118.037184
  • Title of Journal : CIRCULATION
  • Page Numbers: pp.1483-1492

Abstract

BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined.